Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Traws Pharma (TRAW) Net Margin (2016 - 2025)

Traws Pharma (TRAW) has disclosed Net Margin for 14 consecutive years, with 22.87% as the latest value for Q2 2025.

  • For Q2 2025, Net Margin rose 3642275.0% year-over-year to 22.87%; the TTM value through Dec 2025 reached 215.95%, up 2172436.0%, while the annual FY2025 figure was 246.06%, 2443809.0% up from the prior year.
  • Net Margin hit 22.87% in Q2 2025 for Traws Pharma, down from 26461.4% in the prior quarter.
  • Across five years, Net Margin topped out at 26461.4% in Q1 2025 and bottomed at 38248.21% in Q4 2024.
  • Average Net Margin over 5 years is 8863.29%, with a median of 8027.79% recorded in 2023.
  • Year-over-year, Net Margin tumbled -3028036bps in 2024 and then skyrocketed 3642275bps in 2025.
  • Traws Pharma's Net Margin stood at 6719.64% in 2021, then tumbled by -52bps to 10239.29% in 2022, then rose by 22bps to 7967.86% in 2023, then crashed by -380bps to 38248.21% in 2024, then skyrocketed by 100bps to 22.87% in 2025.
  • According to Business Quant data, Net Margin over the past three periods came in at 22.87%, 26461.4%, and 38248.21% for Q2 2025, Q1 2025, and Q4 2024 respectively.